[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Sixth communication: Results of compatibility of CN 3123 (author's transl)].
Etzel M, Wesenberg W·Arzneimittel-Forschung
1. During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) side-effects were reported in only 56 (=4.1%) of the 1371 patients who took part. 2. The numerous laboratory parameters studied in th…